{"title":"18种半合成大麻素-六氢大麻酚(HHC)及其类似物的体外代谢分析及其在真实六氢大麻酚(HHCP)尿液样本中的鉴定","authors":"Shimpei Watanabe, Takaya Murakami, Seiji Muratsu, Saito Takeshi, Yasuo Seto","doi":"10.1093/clinchem/hvaf087","DOIUrl":null,"url":null,"abstract":"Background Hexahydrocannabinol (HHC) and its analogs are recent additions to semi-synthetic cannabinoids in the recreational drug market. Here, the metabolism of 18 HHC analogs was compared to gain a comprehensive understanding of the structure–metabolism relationship of HHC analogs and to identify urinary biomarkers. Additionally, an authentic urine sample obtained from a suspected hexahydrocannabiphorol (HHCP) user was analyzed. Methods Both 9(R)- and 9(S)-epimers of HHC and 8 analogs were separately incubated with human liver microsomes (HLMs) for 1 h. The resulting products and the urine sample were analyzed by liquid chromatography–high-resolution mass spectrometry in an untargeted approach. Results The metabolites were generated by hydroxylation, dehydrogenation, ketone formation, carboxylation, or hydrolysis, either alone or in combination. Concerning the HHC homologs, for 9(R)-epimers, metabolites with multiple biotransformations, e.g., dihydroxy metabolites, were generally more abundant, and the percentage of hydroxy metabolites tended to increase for the longer side-chain homologs, while the reverse was observed for dihydroxy metabolites. For 9(S)-epimers, a metabolite hydroxylated at the methylcyclohexyl moiety was by far the most abundant metabolite, with similar behaviors among hexahydrocannabivarin, hexahydrocannabutol, and HHC, and between hexahydrocannabihexol and HHCP. Acetylated analogs initially underwent hydrolysis to produce almost identical metabolic profiles as the non-acetylated analogs. Methyl ether analogs did not appear to show any particular metabolic trend. In the clinical urine sample, 3 HHCP (di-)hydroxylated metabolites were detected, matching the HLM results. Conclusions The revealed structure–metabolism relationship could serve as a reference for investigating the metabolism of similar cannabinoids, while the identified biomarkers could facilitate drug testing.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"40 1","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In Vitro Metabolic Profiling of 18 Semi-Synthetic Cannabinoids—Hexahydrocannabinol (HHC) and Its Analogs—with Identification in an Authentic Hexahydrocannabiphorol (HHCP) Urine Sample\",\"authors\":\"Shimpei Watanabe, Takaya Murakami, Seiji Muratsu, Saito Takeshi, Yasuo Seto\",\"doi\":\"10.1093/clinchem/hvaf087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Hexahydrocannabinol (HHC) and its analogs are recent additions to semi-synthetic cannabinoids in the recreational drug market. Here, the metabolism of 18 HHC analogs was compared to gain a comprehensive understanding of the structure–metabolism relationship of HHC analogs and to identify urinary biomarkers. Additionally, an authentic urine sample obtained from a suspected hexahydrocannabiphorol (HHCP) user was analyzed. Methods Both 9(R)- and 9(S)-epimers of HHC and 8 analogs were separately incubated with human liver microsomes (HLMs) for 1 h. The resulting products and the urine sample were analyzed by liquid chromatography–high-resolution mass spectrometry in an untargeted approach. Results The metabolites were generated by hydroxylation, dehydrogenation, ketone formation, carboxylation, or hydrolysis, either alone or in combination. Concerning the HHC homologs, for 9(R)-epimers, metabolites with multiple biotransformations, e.g., dihydroxy metabolites, were generally more abundant, and the percentage of hydroxy metabolites tended to increase for the longer side-chain homologs, while the reverse was observed for dihydroxy metabolites. For 9(S)-epimers, a metabolite hydroxylated at the methylcyclohexyl moiety was by far the most abundant metabolite, with similar behaviors among hexahydrocannabivarin, hexahydrocannabutol, and HHC, and between hexahydrocannabihexol and HHCP. Acetylated analogs initially underwent hydrolysis to produce almost identical metabolic profiles as the non-acetylated analogs. Methyl ether analogs did not appear to show any particular metabolic trend. In the clinical urine sample, 3 HHCP (di-)hydroxylated metabolites were detected, matching the HLM results. Conclusions The revealed structure–metabolism relationship could serve as a reference for investigating the metabolism of similar cannabinoids, while the identified biomarkers could facilitate drug testing.\",\"PeriodicalId\":10690,\"journal\":{\"name\":\"Clinical chemistry\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/clinchem/hvaf087\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/clinchem/hvaf087","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
In Vitro Metabolic Profiling of 18 Semi-Synthetic Cannabinoids—Hexahydrocannabinol (HHC) and Its Analogs—with Identification in an Authentic Hexahydrocannabiphorol (HHCP) Urine Sample
Background Hexahydrocannabinol (HHC) and its analogs are recent additions to semi-synthetic cannabinoids in the recreational drug market. Here, the metabolism of 18 HHC analogs was compared to gain a comprehensive understanding of the structure–metabolism relationship of HHC analogs and to identify urinary biomarkers. Additionally, an authentic urine sample obtained from a suspected hexahydrocannabiphorol (HHCP) user was analyzed. Methods Both 9(R)- and 9(S)-epimers of HHC and 8 analogs were separately incubated with human liver microsomes (HLMs) for 1 h. The resulting products and the urine sample were analyzed by liquid chromatography–high-resolution mass spectrometry in an untargeted approach. Results The metabolites were generated by hydroxylation, dehydrogenation, ketone formation, carboxylation, or hydrolysis, either alone or in combination. Concerning the HHC homologs, for 9(R)-epimers, metabolites with multiple biotransformations, e.g., dihydroxy metabolites, were generally more abundant, and the percentage of hydroxy metabolites tended to increase for the longer side-chain homologs, while the reverse was observed for dihydroxy metabolites. For 9(S)-epimers, a metabolite hydroxylated at the methylcyclohexyl moiety was by far the most abundant metabolite, with similar behaviors among hexahydrocannabivarin, hexahydrocannabutol, and HHC, and between hexahydrocannabihexol and HHCP. Acetylated analogs initially underwent hydrolysis to produce almost identical metabolic profiles as the non-acetylated analogs. Methyl ether analogs did not appear to show any particular metabolic trend. In the clinical urine sample, 3 HHCP (di-)hydroxylated metabolites were detected, matching the HLM results. Conclusions The revealed structure–metabolism relationship could serve as a reference for investigating the metabolism of similar cannabinoids, while the identified biomarkers could facilitate drug testing.
期刊介绍:
Clinical Chemistry is a peer-reviewed scientific journal that is the premier publication for the science and practice of clinical laboratory medicine. It was established in 1955 and is associated with the Association for Diagnostics & Laboratory Medicine (ADLM).
The journal focuses on laboratory diagnosis and management of patients, and has expanded to include other clinical laboratory disciplines such as genomics, hematology, microbiology, and toxicology. It also publishes articles relevant to clinical specialties including cardiology, endocrinology, gastroenterology, genetics, immunology, infectious diseases, maternal-fetal medicine, neurology, nutrition, oncology, and pediatrics.
In addition to original research, editorials, and reviews, Clinical Chemistry features recurring sections such as clinical case studies, perspectives, podcasts, and Q&A articles. It has the highest impact factor among journals of clinical chemistry, laboratory medicine, pathology, analytical chemistry, transfusion medicine, and clinical microbiology.
The journal is indexed in databases such as MEDLINE and Web of Science.